BOSTON SCIENTIFIC CORP

NYSE: BSX·Marlborough, Massachusetts·

Price
$43.69
Base IV
$39.97

Valuation snapshot

Above base case

At $43.69, the price sits between our base case ($39.97) and bull case ($67.35).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$39.97
91% of the price · range $20.69–$67.35
Price vs base case
9% above
$43.69 against $39.97
Base casevalued by DCF
Price vs base
Priceclose 11‑16

The price has fallen 4.6% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.

Whisker on the base case runs bear $20.69 to bull $67.35. Values per share.

Price against each value

Bear case
$20.69
Price 111% above
No growth
…
—
Base case
$39.97
Price 9% above
Researched bygemini-3.8-flash-medium
Valuation Nov 5, 2026 · Price as of Nov 16, 2026How we got here

What does Boston Scientific do?

Boston Scientific develops and manufactures medical devices for physicians to diagnose and treat cardiovascular, respiratory, digestive, and urological conditions through minimally invasive procedures.

It brought in $21.1B of sales in the 12 months to Sep 2026.

Led by Michael F. Mahoney, Chairman of the Board, President and Chief Executive Officer since 2012. Notice of 2024 Annual Meeting of Stockholders and Proxy Statement

AXIOS stent and delivery systemImage: Boston Scientific
Industry
Healthcare
Based in
Marlborough, Massachusetts
Trades on
NYSE as BSX

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 17¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 34¢ of every dollar.

  • Making what it sells31¢
  • Research and development10¢
  • Sales, marketing and admin34¢
  • Everything else it takes to operate7¢
  • Interest and other costs1¢
  • Tax1¢
  • Left as profit17¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Boston Scientific, and for what?

Boston Scientific makes medical devices used to diagnose and treat conditions affecting the heart, blood vessels, digestive and urinary systems, and nervous system. It earns revenue by selling these devices and related technologies to health care providers around the world.

Its products are bought mainly by hospitals, clinics, outpatient facilities, medical offices and other health care providers; group purchasing organizations and hospital networks also account for a substantial portion of sales.

  • Cardiovascular

    66%

    Devices and technologies for heart, blood vessel and cancer treatments, including electrophysiology, WATCHMAN, cardiac rhythm management and vascular therapies.

  • Endoscopy

    15%

    Minimally invasive devices for diagnosing and treating digestive and pancreaticobiliary conditions, and supporting weight loss.

    AXIOS stent and delivery systemImage: Boston Scientific
  • Urology

    13%

    Devices for kidney stones, prostate conditions, erectile dysfunction, incontinence and pelvic floor disorders.

    LithoVue Elite single-use digital flexible ureteroscope systemImage: Boston Scientific
  • Neuromodulation

    6%

    Devices to manage chronic pain and treat neurological movement disorders.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Galway campus — Galway, Ireland. The site combines medical device manufacturing with cardiovascular R&D, and Boston Scientific announced a €75 million investment to expand its development capacity.
  • Maple Grove facility — Maple Grove, United States. Boston Scientific identifies Maple Grove as both a principal manufacturing facility and an R&D center, making it important to device production and development.
  • Clonmel facility — Clonmel, Ireland. Clonmel is one of Boston Scientific’s principal Irish manufacturing facilities and also houses an R&D center.
  • Coyol facility — Alajuela, Costa Rica. The 2025 Form 10-K identifies Coyol as a principal owned manufacturing facility within Boston Scientific’s Costa Rican production network.
  • Arden Hills facility — Arden Hills, United States. Boston Scientific lists Arden Hills as both a principal manufacturing facility and an R&D center, tying the site to production and product development.
See them on the globe

Boston Scientific 2025 Form 10-K

How is the business doing?

Sales grew from $9.9B in 2020 to $20.1B in 2025, about 15% a year.

Running the business leaves about 19¢ of each sales dollar as operating profit, up from 1¢ in 2020.

After paying for its upkeep and new investment, it had $3.3B of cash to spare in the 12 months to Sep 2026.

Sales$20.1B
20162025
Operating margin18%
20162025
Free cash flow$3.7B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

The company says it exists to improve patients’ health around the world with innovative medical solutions.

“transform lives through innovative medical solutions that improve the health of patients around the world”

Boston Scientific 2025 Form 10-K

Who is responsible for the plan?

Roles checked November 14, 2026.

What management says it is working on now:

  • Address WATCHMAN market headwinds

    Management plans more physician education and evidence sharing, stronger engagement with hospitals, and direct outreach to help appropriate patients learn about the treatment.

    Boston Scientific Q2 2026 Earnings Call Transcript
  • Improve U.S. electrophysiology performance

    Management is focused on expanding access to its pulsed field ablation products and developing its product lineup, while responding to competitive share shifts.

    Boston Scientific Q2 2026 Earnings Call Transcript
  • Strengthen urology and cardiac rhythm management

    Management expects business improvements as it addresses gaps in urology and prepares new cardiac rhythm management products.

    Boston Scientific Q2 2026 Earnings Call Transcript
  • Control costs and reinvest for growth

    A restructuring program is intended to lower ongoing costs while directing resources toward areas management sees as having strong long-term opportunities.

    Boston Scientific Q2 2026 Earnings Call Transcript
  • Expand through innovation and global markets

    The company plans to invest in research, improve existing products, develop new technologies and grow in international and emerging markets.

    Boston Scientific 2025 Form 10-K
Organic revenue growth, 2026
5% to 6%
Boston Scientific Q2 2026 Earnings Call Transcript
Adjusted operating margin expansion, 2026
0 to 25 basis points
Boston Scientific Q2 2026 Earnings Call Transcript
Adjusted earnings per share growth, 2026
7% to 8%
Boston Scientific Q2 2026 Earnings Call Transcript
Annual run-rate savings from restructuring, Exiting 2029
Approximately $500 million
Boston Scientific Q2 2026 Earnings Call Transcript
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q3 2026 it sold 1% more than a year earlier. The year before, quarters averaged 14%.

Its operating margin is narrower than a year ago: 16¢ per sales dollar, against 21¢.

Since Oct 2026 the share price has risen 2%, from $42.69 to $43.69.

Bull $67.35Base $39.97Bear $20.69Oct 30Nov 16 · $43.69
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $25.07 to $39.97 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Competition and fast-changing technology

    Rivals, lower-priced products and alternative treatments may take customers or make the company’s products less competitive. Delayed or unsuccessful product development could also hurt sales.

    From the company's own filingsWould hit how fast sales growBoston Scientific 2025 Form 10-K

  2. Pricing, procedure and reimbursement pressure

    Hospitals and other buyers are consolidating, while governments and insurers seek to contain health care costs. Lower prices, reduced coverage or fewer procedures using its devices could weaken sales.

    From the company's own filingsWould hit how fast sales growBoston Scientific 2025 Form 10-K

  3. Regulatory approval and compliance

    Medical devices need approvals in the markets where they are sold, and requirements can change. Delays, recalls or other regulatory actions could restrict sales or raise costs.

    From the company's own filingsWould hit how fast sales growBoston Scientific 2025 Form 10-K

  4. Product development and launch execution

    New products require research, clinical studies and regulatory approval, and may not gain acceptance. Delays or weak results could limit growth, especially for products management expects to contribute meaningfully.

    From the company's own filingsWould hit how fast sales growBoston Scientific 2025 Form 10-K

  5. Supply interruptions and rising costs

    Some components come from single suppliers, and manufacturing or sterilization disruptions could limit product availability. Material shortages, tariffs and higher costs could also pressure results.

    From the company's own filingsWould hit how much of each sale it keepsBoston Scientific 2025 Form 10-K

  6. Acquisition and debt exposure

    Acquisitions take time and resources to integrate and may not deliver expected benefits. The company also says higher debt or weaker cash flow could raise borrowing costs and limit financial flexibility.

    From the company's own filingsWould hit how much of each sale it keepsBoston Scientific 2025 Form 10-K

  7. Management provided a Q4 2026 sales guidance projection ranging between a 3% decline and a 1% decline YoY.

    From our researchWould hit how fast sales growBoston Scientific Q3 2026 Earnings Release

  8. Operational and computer network remediation costs in late 2026 drove quarterly operating margin down to 16.12%.

    From our researchWould hit how much of each sale it keepsBoston Scientific Form 10-Q Q3 2026

Is it a good business?

From 2016 to 2025 it earned between -0% and 9% on the capital invested in it, a median of 6%. Its cost of capital in the latest valuation is 7.4%; returns were above it in 3 of the 10 years.

From 2016 to 2025 it earned between -1% and 34% on its shareholders' equity, a median of 7%.

Over 10 years its operating margin ranged from 1¢ to 18¢ per sales dollar, a median of 14¢. Gross margin ran from 65¢ to 71¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital9%
20162025

Cost of capital 7.4%

Return on equity12%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 19%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 2.9% in a year, so each remaining share owns a slightly bigger slice.

It owes $11.3B more than it holds in cash, about 2.9 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $43.69. Our put its value between $20.69 and $67.35, with $39.97 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $20.69

This scenario envisions Boston Scientific's expansion cooling significantly from its recent twenty percent annual pace down to low single digits as competition intensifies in heart devices and temporary operational disruptions linger.

Base case, $39.97

This scenario projects that Boston Scientific rebounds from recent operational bottlenecks to deliver mid-single-digit sales growth and steady profit efficiency, supported by ongoing worldwide demand for its flagship cardiac and surgical technologies.

Bull case, $67.35

This scenario models a powerful growth reacceleration back toward double digits as international market expansion for next-generation ablation tools and stroke-prevention implants drives market share gains and expanding profitability.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 9%

For Boston Scientific to be worth today's $43.69, sales would need to grow about 8.1% a year. We assume 6.3%. Over the last 5 years, sales grew 12.9% a year.

−5%0%+5%+10%+15%We assume 6.3%Price needs 8.1%Past 5 yrs 12.9%

Or, if sales grow 6.3% as we assume, the price works with a profit margin of 21.6% (we assume 20.0%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 8.1% a year?

Try your own numbers

We're moderately sure of this range: it scores 64 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $39.97 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average6.3%
  • Operating margin20.0%
  • Long-term growth rate2.8%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$39.97 -8.5%

Build